{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:41:11Z","timestamp":1740123671190,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10689-021-00262-0","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T04:02:34Z","timestamp":1621224154000},"page":"289-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A recurrent pathogenic BRCA2 exon 5\u201311 duplication in the Christian Arab population in Israel"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7490-8965","authenticated-orcid":false,"given":"Gili","family":"Reznick Levi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gal","family":"Larom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vered","family":"Ofen Glassner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Ekhilevitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitzan","family":"Sharon Swartzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Paperna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagit","family":"Baris-Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"262_CR1","unstructured":"WHO | Breast cancer (2018) http:\/\/www.who.int\/cancer\/prevention\/diagnosis-screening\/breast-cancer\/en\/. Accsessed 31 Oct 2020."},{"key":"262_CR2","unstructured":"The Israeli National Cancer registry, Breast Cancer in Israel, Update incidence and mortality data, 2018, Ministry of Health, Israel. https:\/\/www.health.gov.il\/PublicationsFiles\/breast_cancer_SEPT2018.pdf"},{"key":"262_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMcp071286","volume":"357","author":"M Robson","year":"2007","unstructured":"Robson M, Offit K (2007) Management of an inherited predisposition to breast cancer. N Engl J Med 357:154\u2013162. https:\/\/doi.org\/10.1056\/NEJMcp071286","journal-title":"N Engl J Med"},{"key":"262_CR4","unstructured":"Pilarski R, Berry MP, Jude S, et al (2019) Continue NCCN Guidelines Panel Disclosures Breast surgical oncology NCCN Guidelines Version 1.2020 Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic"},{"key":"262_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2174\/1389450118666170711151518","volume":"19","author":"D Kamel","year":"2018","unstructured":"Kamel D, Gray C, Walia JS, Kumar V (2018) PARP inhibitor drugs in the treatment of breast, ovarian, prostate and pancreatic cancers: an update of clinical trials. Curr Drug Targets 19:21\u201337. https:\/\/doi.org\/10.2174\/1389450118666170711151518","journal-title":"Curr Drug Targets"},{"key":"262_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10549-014-2987-6","volume":"145","author":"AG Arnold","year":"2014","unstructured":"Arnold AG, Otegbeye E, Fleischut MH et al (2014) Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. Breast Cancer Res Treat 145:625\u2013634. https:\/\/doi.org\/10.1007\/s10549-014-2987-6","journal-title":"Breast Cancer Res Treat"},{"key":"262_CR7","unstructured":"The Central Bureau of Statistics. https:\/\/www.cbs.gov.il\/en\/subjects\/Pages\/Population.aspx. Accessed 13 Feb 2020"},{"key":"262_CR8","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s10549-017-4474-3","volume":"166","author":"J Zidan","year":"2017","unstructured":"Zidan J, Zhou AY, van den Akker J et al (2017) Inherited predisposition to breast and ovarian cancer in non-Jewish populations in Israel. Breast Cancer Res Treat 166:881\u2013885. https:\/\/doi.org\/10.1007\/s10549-017-4474-3","journal-title":"Breast Cancer Res Treat"},{"key":"262_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-019-05379-6","volume":"178","author":"R Bernstein-Molho","year":"2019","unstructured":"Bernstein-Molho R, Barnes-Kedar I, Ludman MD et al (2019) The yield of full BRCA1\/BRCA2 genotyping in Israeli Arab high-risk breast\/ovarian cancer patients. Breast Cancer Res Treat 178:231\u2013237. https:\/\/doi.org\/10.1007\/s10549-019-05379-6","journal-title":"Breast Cancer Res Treat"},{"key":"262_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2407-7-14","volume":"7","author":"L Kadouri","year":"2007","unstructured":"Kadouri L, Bercovich D, Elimelech A et al (2007) A novel BRCA-1 mutation in Arab kindred from east Jerusalem with breast and ovarian cancer. BMC Cancer 7:14. https:\/\/doi.org\/10.1186\/1471-2407-7-14","journal-title":"BMC Cancer"},{"key":"262_CR11","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1136\/jmedgenet-2018-105824","volume":"57","author":"T Paperna","year":"2020","unstructured":"Paperna T, Sharon-Shwartzman N, Kurolap A et al (2020) Homozygosity for CHEK2 p.Gly167Arg leads to a unique cancer syndrome with multiple complex chromosomal translocations in peripheral blood karyotype. J Med Genet 57:500\u2013504. https:\/\/doi.org\/10.1136\/jmedgenet-2018-105824","journal-title":"J Med Genet"},{"key":"262_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/jmg.2005.031781","volume":"43","author":"L Van Maldergem","year":"2006","unstructured":"Van Maldergem L, Siitonen HA, Jalkh N et al (2006) Revisiting the craniosynostosis-radial ray hypoplasia association: Baller-Gerold syndrome caused by mutations in the RECQL4 gene. J Med Genet 43:148\u2013152. https:\/\/doi.org\/10.1136\/jmg.2005.031781","journal-title":"J Med Genet"},{"key":"262_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23390","author":"A Baert","year":"2018","unstructured":"Baert A, Machackova E, Coene I et al (2018) Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11. Hum Mutat. https:\/\/doi.org\/10.1002\/humu.23390","journal-title":"Hum Mutat"},{"key":"262_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10549-015-3662-2","volume":"155","author":"T Yablonski-Peretz","year":"2016","unstructured":"Yablonski-Peretz T, Paluch-Shimon S, Gutman LS et al (2016) Screening for germline mutations in breast\/ovarian cancer susceptibility genes in high-risk families in Israel. Breast Cancer Res Treat 155:133\u2013138. https:\/\/doi.org\/10.1007\/s10549-015-3662-2","journal-title":"Breast Cancer Res Treat"},{"key":"262_CR15","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1002\/ajmg.a.33746","volume":"152A","author":"M Khayat","year":"2010","unstructured":"Khayat M, Hardouf H, Zlotogora J, Shalev SA (2010) High carriers frequency of an apparently ancient founder mutation p.Tyr322X in the ERCC8 gene responsible for cockayne syndrome among christian arabs in Northern Israel. Am J Med Genet 152A:3091\u20133094. https:\/\/doi.org\/10.1002\/ajmg.a.33746","journal-title":"Am J Med Genet"},{"key":"262_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/humu.21154","volume":"31","author":"V Laugel","year":"2010","unstructured":"Laugel V, Dalloz C, Durand M et al (2010) Mutation update for the CSB\/ERCC6 and CSA\/ERCC8 genes involved in Cockayne syndrome. Hum Mutat 31:113\u2013126. https:\/\/doi.org\/10.1002\/humu.21154","journal-title":"Hum Mutat"},{"key":"262_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1634\/theoncologist.2014-036420","volume":"20","author":"NS El Saghir","year":"2015","unstructured":"El Saghir NS, Zgheib NK, Assi HA et al (2015) BRCA1 and BRCA2 Mutations in Ethnic Lebanese Arab Women With High Hereditary Risk Breast Cancer. Oncologist 20:357\u2013364. https:\/\/doi.org\/10.1634\/theoncologist.2014-036420","journal-title":"Oncologist"},{"key":"262_CR18","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1158\/0008-5472.CAN-08-0599","volume":"68","author":"MD Palma","year":"2008","unstructured":"Palma MD, Domchek SM, Stopfer J et al (2008) The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res 68:7006\u20137014. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0599","journal-title":"Cancer Res"},{"key":"262_CR19","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.711222","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA - J Am Med Assoc 317:2402\u20132416. https:\/\/doi.org\/10.1001\/jama.2017.711222","journal-title":"JAMA - J Am Med Assoc"},{"key":"262_CR20","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1093\/hmg\/dds101","volume":"21","author":"W Roeb","year":"2012","unstructured":"Roeb W, Higgins J, King MC (2012) Response to DNA damage of CHEK2 missense mutations in familial breast cancer. Hum Mol Genet 21:2738\u20132744. https:\/\/doi.org\/10.1093\/hmg\/dds101","journal-title":"Hum Mol Genet"},{"key":"262_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1399-0004.2012.01917.x","volume":"83","author":"F Coulet","year":"2013","unstructured":"Coulet F, Fajac A, Colas C et al (2013) Germline RAD51C mutations in ovarian cancer susceptibility. Clin Genet 83:332\u2013336. https:\/\/doi.org\/10.1111\/j.1399-0004.2012.01917.x","journal-title":"Clin Genet"},{"key":"262_CR22","doi-asserted-by":"crossref","unstructured":"Loveday C, Turnbull C, Ruark E, et al (2012) Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat. Genet. 44:475\u2013476. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22538716","DOI":"10.1038\/ng.2224"},{"key":"262_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10549-015-3674-y","volume":"155","author":"L J\u00f8nson","year":"2016","unstructured":"J\u00f8nson L, Ahlborn LB, Steffensen AY et al (2016) Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and\/or ovarian cancer. Breast Cancer Res Treat 155:215\u2013222. https:\/\/doi.org\/10.1007\/s10549-015-3674-y","journal-title":"Breast Cancer Res Treat"},{"key":"262_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10549-014-3078-4","volume":"147","author":"A Blanco","year":"2014","unstructured":"Blanco A, Guti\u00e9rrez-Enr\u00edquez S, Santamari\u00f1a M et al (2014) RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families. Breast Cancer Res Treat 147:133\u2013143. https:\/\/doi.org\/10.1007\/s10549-014-3078-4","journal-title":"Breast Cancer Res Treat"},{"key":"262_CR25","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.2015.61.2408","volume":"33","author":"H Song","year":"2015","unstructured":"Song H, Dicks E, Ramus SJ et al (2015) Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol 33:2901\u20132907. https:\/\/doi.org\/10.1200\/JCO.2015.61.2408","journal-title":"J Clin Oncol"},{"key":"262_CR26","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1093\/hmg\/dds115","volume":"21","author":"A Osorio","year":"2012","unstructured":"Osorio A, Endt D, Fern\u00e1ndez F et al (2012) Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families. Hum Mol Genet 21:2889\u20132898. https:\/\/doi.org\/10.1093\/hmg\/dds115","journal-title":"Hum Mol Genet"},{"key":"262_CR27","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1007\/s00432-018-2763-9","volume":"144","author":"S Bonache","year":"2018","unstructured":"Bonache S, Esteban I, Moles-Fern\u00e1ndez A et al (2018) Multigene panel testing beyond BRCA1\/BRCA2 in breast\/ovarian cancer Spanish families and clinical actionability of findings. J Cancer Res Clin Oncol 144:2495\u20132513. https:\/\/doi.org\/10.1007\/s00432-018-2763-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"262_CR28","doi-asserted-by":"publisher","unstructured":"Tedaldi G, Tebaldi M, Zampiga V, et al (2017) Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer. Oncotarget 8:47064\u201347075. https:\/\/doi.org\/https:\/\/doi.org\/10.18632\/oncotarget.16791","DOI":"10.18632\/oncotarget.16791"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-021-00262-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-021-00262-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-021-00262-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T07:18:14Z","timestamp":1655363894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-021-00262-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["262"],"URL":"https:\/\/doi.org\/10.1007\/s10689-021-00262-0","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"type":"print","value":"1389-9600"},{"type":"electronic","value":"1573-7292"}],"subject":[],"published":{"date-parts":[[2021,5,17]]},"assertion":[{"value":"20 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Reznick Levi Gili reported personal fees from AstraZeneca outside the submitted work. No other disclosers were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}